For example, CD34(+)/CD10(−) CLCs in HR B-ALL patients consisted of 25% of the CLC population isolated on day 15 of therapy, then decreased to virtually none on day 22, present again on day 29 (end of induction therapy) at 50% of the isolated CLC population, and then not detected on day 85 (end of consolidation). The gene discussed is MME; the disease is acute lymphoblastic leukemia.